Paul Matisse predicts Biohaven could resolve the partial clinical hold on their KV7 drug within one month.
“Biohaven's saving, you know, they could resolve this in a month.”
→ Read the source episode
Our resolution criterion
disputableFDA lifts partial clinical hold on Biohaven's KV7 inhibitor or Biohaven provides update resolving the metabolite safety concern
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.